[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"turner-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:turner-syndrome":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,24,0,[8,47,95,126,153,185,214,236,265,286,305,329,358,380,408,427,450,473,494,517,536,572,621,642],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100435319","gonadal-tissue-freezing-for-fertility-preservation-in-individuals-at-risk-for-ovarian-dysfunction-premature-ovarian-insufficiency-and-clinically-indicated-gonadectomy-100435319",false,"NCT04948658","Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Individuals with Turner Syndrome prior to menarche aged 2 years to 12 years whose families seek to store ovarian tissue for possible future use.\n\n   Or\n\n   Individuals with galactosemia (age 2-21)\n\n   Or\n\n   Adolescent females up to age 21 years old, who have undergone menarche and are subsequently diagnosed with premature ovarian insufficiency and their last menstrual period occurred within 2 years of presentation. Diagnosis of POI is based on 2 elevated FSH concentrations obtained over 1 month apart.\n\n   Or\n\n   Children or adolescents aged 2-24 years old who have diminished ovarian reserve based on laboratory findings or who respond poorly to ovarian stimulation for egg freezing.\n\n   Or\n\n   Individuals with variations in sex characteristics (or differences in sex development, DSD) including Turner syndrome with Y chromosome material who undergo prophylactic gonadectomy for clinical indications.\n\n   Or\n\n   Individuals (2-35 years) receiving high-risk gonadotoxic therapy at the NIH Clinical Center who are at high risk for developing premature ovarian insufficiency and infertility.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Ability of subject, parents, or guardian to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Individuals older than 7 years with psychological, psychiatric, or other conditions which prevent giving fully informed consent or assent.\n2. Individuals with a pelvic mass tumor noted on pre-operative ultrasound, will undergo usual care for the underlying condition and will not undergo oophorectomy for ovarian tissue cryopreservation.\n3. Individuals whose underlying medical condition significantly increases their risk of complications from anesthesia and surgery.\n4. Females with POI due to chemotherapy or radiation treatment\n5. Pregnancy or lactation\n6. Individuals with VSC who choose to retain gonads after clinical consulting.\n7. Individuals with Turner Syndrome who have an undetectable AMH based on testing laboratory reference range.","ALL","2 Years","35 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Background:\n\nTurner Syndrome, galactosemia, and premature ovarian insufficiency are all conditions that may make it very hard or impossible for a person to become pregnant and have their own child. Researchers want to learn more about why this happens and if freezing Gonadal tissue allows for fertility preservation.\n\nObjective:\n\nTo find out why people with certain conditions have can have premature ovarian insufficiency (POI or early menopause) and individuals with variations in sex characteristics have trouble getting pregnant and if freezing the gonads tissue from them will help to have their own child in the future.\n\nEligibility:\n\nIndividuals aged 2-21 who have Turner Syndrome or galactosemia. Also, females aged 13-21 with premature ovarian insufficiency, individuals with variations in sex characteristics, and individuals 2-35 receiving high-risk gonadotoxic therapy\n\nDesign:\n\nParticipants will be screened with a medical history.\n\nParticipants may have a physical exam and blood tests. Their body measurements may be taken. These include weight, height, arm span, skin fold, and sitting height. They may fill out surveys about their quality of life, body image, and health.\n\nParticipants may have a transabdominal pelvic ultrasound. A probe will be placed on their belly and will take pictures of the organs in the pelvis. They may have a transvaginal pelvic ultrasound performed while asleep in the operating room if needed.\n\nParticipants may have surgery to remove an gonads and skin biopsy. The removed tissue will be frozen and stored. The tissue will have to be stored for many years. NIH will pay to store the tissue for 1 year. After that, participants will have to pay for storage.\n\nA piece of the gonads (no more than 20%) will be used for research\n\nTravel, lodging and meals for participants traveling greater than 50 miles will be reimbursed based off the government rate. Local participants will not be reimbursed.\n\nParticipants will have a checkup 6 weeks after surgery one or more follow-up visits 6-18 months after surgery. They may have phone follow-up every 12-24 months after surgery.\n\nParticipation will last 30 years.",[24,25,26,27,28,29],"Turner Syndrome","Post-menarcheal Adolescents","Ovarian Disfunction","Galactosemia","Variations in Sex Characteristics","Differences in Sex Development",[31,32,33,28,29],"OVARIAN FUNCTION","Natural History","follicle loss","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2021-09-13",{"date":42,"type":20},"2030-07-31",{"name":44,"class":45},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100609997","phase-3-trial-investigating-the-efficacy-and-safety-of-weekly-lonapegsomatropin-compared-to-daily-somatropin-in-children-and-adolescents-with-short-stature-or-growth-failure-due-to-growth-hormone-sufficient-disorders-100609997","NCT07221851","Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders","A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature","Inclusion Criteria:\n\n1. Chronological age between ≥2 and \\\u003C18 years, at start of screening.\n2. Naïve to growth hormone and growth hormone promoting therapies.\n3. Prepubertal.\n4. Able to stand without assistance.\n5. Diagnosis of TS, SHOX-D, SGA, or ISS with impaired growth or short stature, according to the following disease-specific criteria:\n\n   TS or SHOX-D (Léri-Weill dyschondrosteosis):\n   1. Diagnosis confirmed by a genetic test. NOTE: Historical test results are acceptable for proof of diagnosis. For karyotypes, a minimum of 20 cells must be counted.\n   2. Impaired growth or short stature defined as:\n\n   (i.) AHV \\\u003C25th percentile over a time span of 6-16 months prior to screening utilizing a historical height properly documented in a health care setting (self-measurement record is not accepted) OR (ii.) Height \\\u003C5th percentile for sex and age according to the Centers for Disease Control Growth Charts for the United States\n\n   SGA without catch-up growth:\n\n   c. Birth weight and\u002For birth length \\\u003C -2.0 SDS for gestational age according to the 2006 World Health Organization Child Growth Standards. For infants born premature, the Fenton Preterm Infant Growth Chart (Fenton 2013) should be used.\n\n   d. Impaired growth or short stature defined as: (i.) AHV \\\u003C25th percentile over a time span of 6-16 months prior to screening properly documented in a health care setting (self-measurement record is not accepted) OR (ii.) Height \\\u003C -2.0 SDS for age and sex according to the 2000 Centers for Disease Control Growth Charts for the United States for children ≥ 3 years or height \\\u003C -2.5 SDS for age and sex according to the for children ≥ 2 years and \\\u003C 3 years\n\n   ISS:\n\n   e. Height \\\u003C -2.25 SDS for sex and age according to the Centers for Disease Control Growth Charts for the United States with no identifiable cause for short stature.\n\n   f. Documented normal GH-IGF-1 axis, defined as either: (i.)IGF-1 SDS \\>0 at screening based on central laboratory OR (ii.)Historical documentation of normal peak GH upon stimulation test (as defined by local institution) g. 46,XX chromosome as determined by karyotype or microarray if female. For karyotypes, a minimum of 30 cells must be counted.\n6. If on hormone replacement therapies for any hormone deficiencies other than growth hormone (e.g., adrenal, thyroid), must be on adequate and stable doses for ≥4 weeks prior to and throughout screening.\n7. Written, signed informed consent provided by parent(s) or legal guardian(s) of the participant. Assent should be signed by participant as required by IRB\u002FHREC\u002FIEC.\n\nExclusion Criteria:\n\n1. Advanced bone age X-ray by central reading defined as \\>20% above chronological age in months (Greulich 1959).\n2. Closed epiphyses as defined as bone age of ≥14.0 years in females or ≥16.0 years in males.\n3. Current clinical diagnosis of diabetic retinopathy\n4. Any diagnosis or presence at screening of the following:\n\n   1. Untreated moderate or severe sleep apnea as determined by formal (local) read of an inpatient or at-home sleep study.\n   2. Prader Willi syndrome with severe obesity, history of severe upper airway obstruction, or severe respiratory impairment.\n5. Signs\u002Fsymptoms of intracranial hypertension, active proliferative retinopathy.\n6. Uncontrolled hypo- or hyperthyroidism.\n7. Uncontrolled diabetes mellitus (defined as: HbA1c \\>7.5% from central laboratory at screening).\n8. Known history or diagnosis of any gastrointestinal inflammatory condition, HIV, radiation exposure, other skeletal dysplasias, growth hormone deficiency, and\u002For cardio-thoracic surgery due to their independent effects on growth.\n9. Any significant hepatic or renal abnormality, such as abnormal renal function (defined as eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2).\n10. Undiagnosed or uncontrolled hypertension.\n11. Receiving treatment with any agent that might influence growth or interfere with GH secretion or action including any sex steroids and stimulants for attention-deficit\u002Fhyperactivity disorder (ADHD).\n12. High dose inhaled glucocorticoid for more than 28 consecutive days total over the course of 12 months.\n13. Female who is pregnant, plans to be pregnant, or breastfeeding.\n14. Participation in another interventional clinical trial involving an investigational compound within 90 days prior to screening or in parallel to this trial.\n15. Any disease or condition that, in the judgement of the investigator, may make the participant unlikely to comply with the requirements of the protocol or any condition that presents undue risk from the investigational product or trial procedures.\n16. Exclusion Criteria only applicable to TS:\n\n    1. Presence of Y chromosome material on genetic testing without history of gonadectomy.\n    2. Less than 10% of 45,X mosaicism.\n    3. Any known, clinically significant, congenital or acquired cardiovascular dysfunction that might interfere with growth.\n17. Exclusion Criteria only applicable to SGA:\n\n    a. Any known clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements: (i.)Chromosomal aneuploidy, significant gene mutations, or medical syndromes with short stature, including but not limited to Turner syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, abnormal SHOX-1 gene analysis or absence of GH receptors.\n\n    (ii.)Congenital abnormalities (causing skeletal abnormalities), including but not limited to skeletal dysplasias.\n18. Exclusion Criteria only applicable to ISS:\n\n    1. Known history of any condition that causes disproportionate short stature (i.e. skeletal dysplasias), chromosomal aneuploidy, significant gene mutations, or medical syndromes with short stature, including but not limited to Turner syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, abnormal SHOX-1 gene analysis or absence of gH receptors.","17 Years",{"count":56,"type":20},186,"INTERVENTIONAL",[59],"PHASE3","This basket trial will enroll prepubertal children and adolescents with clinically diagnosed and genetically confirmed (if applicable) TS, SHOX-D, SGA, or ISS between ages of ≥2 and \\\u003C18 years with open growth plates. The purpose of the study is to see how well treatment with once-weekly lonapegsomatropin works compared to treatment with daily somatropin. Approximately 186 participants will be distributed equally (1:1), to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year. This trial will be conducted in the United States, France, Germany, Italy, Romania, Spain and South Korea.",[24,62,63,64],"Short Stature Homeobox Gene Mutation","Idiopathic Short Stature","Small for Gestational Age at Delivery",[24,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,62,83,63],"Noonan Syndrome","Growth Hormone","Short Stature","Growth Failure","Sex Chromosome Disorders","Chromosome Disorders","Endocrine System Diseases","Pituitary Hormones, Anterior","Pituitary Hormones","Hormones","Hormone Substitutes","Human Growth Hormone","Lonapegsomatropin","Sex Chromosome Disorders of Sex Development","Impaired Growth","somatropin","Growth Hormone Sufficiency","Short Stature Children Born Small for Gestational Age","2026-06-19",{"date":86,"type":38},"2026-06-23",{"date":88,"type":38},"2025-12-12",{"date":90,"type":20},"2029-03",{"name":92,"class":93},"Ascendis Pharma A\u002FS","INDUSTRY",25,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":105,"conditions":106,"keywords":111,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100241172","natural-history-of-noncirrhotic-portal-hypertension-100241172","NCT02417740","Natural History of Noncirrhotic Portal Hypertension","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Male or female, aged \\>= 18 years of age, and minors 12-17 years of age.\n* Women of childbearing potential must agree to use birth control unless they are menopausal or had hysterectomy.\n* Known diagnosis of NCPH, or to be at the risk for NCPH by virtue of underlying disease processes such as but not limited to; CGD, SCD, Mastocytosis, CVID, CF, and CHF.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy.\n* Evidence of other forms of liver disease that typically result in cirrhosis.\n* Evidence of active Chronic Hepatitis B infection as defined by the presence of hepatitis B surface antigen (HBsAg) in serum and elevated HBV DNA (\\>10,000 IU\u002FmL).\n* Hepatitis C as defined by the presence of hepatitis C RNA in serum.\n* Evidence of other liver disease such as primary sclerosing cholangitis, primary biliary cirrhosis, Wilson s disease, autoimmune hepatitis as defined by either liver histology or laboratory abnormalities.\n* Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy or homozygosity for C282Y. Patients with iron saturation indices of \\>45% and serum ferritin levels of \\>300 ng\u002Fml for men and \\>250 ng\u002Fml for women will undergo genetic testing for hemochromatosis.\n* Bile duct obstruction as suggested by imaging studies done within the previous six months.\n* The presence of cirrhosis confirmed by liver biopsy.\n* Active substance abuse, such as alcohol, inhaled or injection drugs within the previous one year (assessed during subject interviews by subject self-report).\n* Evidence of hepatocellular carcinoma; either alpha-fetoprotein (AFP) levels greater than 50 ng\u002Fml (normal \\\u003C6.6ng\u002Fml) and\u002For ultrasound (or other imaging study) demonstrating a mass suggestive of liver cancer.\n* Evidence of cholangiocarcinoma as suggested by liver histology.\n* Any other severe condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study.\n* Inability to comply or give written informed consent.","12 Years","100 Years",{"count":104,"type":20},400,"Background:\n\n\\- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs. Many people may not even know that they have a liver disease. There are no specific treatments for NCPH.\n\nObjectives:\n\n\\- To learn more about how NCPH develops over time.\n\nEligibility:\n\n\\- People age 12 and older who have NCPH or are at risk for getting it. In the past year, they cannot have had other types of liver disease that typically result in cirrhosis, liver cancer, or active substance abuse.\n\nDesign:\n\n* Participants will have 2 screening visits.\n* Visit 1: to see if they have or may develop NCPH.\n* Medical history\n* Physical exam\n* Urine and stool studies\n* Abdominal ultrasound\n* Fibroscan. Sound waves measure liver stiffness.\n\n\\\u003CTAB\\>- Visit 2:\n\n* Blood tests\n* Abdominal MRI\n* Echocardiogram\n* Questionnaire\n* Liver blood vessel pressure (hepatic venous portal gradient (HVPG)) measurement. This is done with a small tube inserted in a neck vein.\n* They may have a liver biopsy.\n* All participants will visit the clinic every 6 months for a history, physical exam, and blood tests. They will also repeat some of the screening tests yearly.\n* Participants with NCPH will also have:\n* Upper endoscopy test. A tube inserted in the mouth goes through the esophagus and stomach.\n* At least every 2 years: Esophagogastroduodenoscopy.\n* At least every 4 years: testing including HVPG measurements and liver biopsy.\n* Participants without NCPH will also have:\n* Liver biopsy and HVPG measurements to see if they have NCPH.\n* Every 2 years: abdominal MRI and stool studies.\n* The study will last indefinitely.",[107,108,24,109,110],"Cystic Fibrosis","Immunologic Deficiency Syndrome","Congenital Hepatic Fibrosis","Idiopathic Non-Cirrhotic Portal Hypertension",[112,113,114,115,116,32],"Portal Hypertension","Portal Fibrosis","Liver Disease","Varices","Splenomegaly","2026-05-29",{"date":119,"type":38},"2026-06-01",{"date":121,"type":38},"2015-07-27",{"date":123,"type":20},"2029-09-04",{"name":125,"class":45},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":133,"minAge":16,"maxAge":101,"enrollmentInfo":134,"targetDuration":4,"studyType":57,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":152},"100640722","phase-3-the-efficacy-and-safety-of-inpegsomatropin-injection-in-children-with-turner-syndrome-ts-and-short-stature-100640722","NCT07614152","The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature","Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Inpegsomatropin Injection Versus Givopegsomatropin Solution Injection in the Treatment of Short Stature in Children With Turner Syndrome.","Inclusion Criteria:\n\n* Prepubertal girls at Tanner stage I, with age ≥ 2 years and \\\u003C 12 years at the time of informed consent signature.\n* With clinical manifestations of Turner syndrome and a confirmed diagnosis of Turner syndrome based on peripheral blood karyotype analysis (karyotype analysis of at least 30 metaphase cells).\n* At screening, bone age is delayed relative to chronological age or advanced by no more than 1 year (i.e., bone age - chronological age ≤ 1 year).\n* At screening, height is below -2 standard deviations (-2SD) of the mean for age and gender; height reference is shown in Appendix 1.\n* No prior systematic pharmacological growth-promoting treatment (continuous use for ≥ 1 month), including but not limited to growth hormone, insulin-like growth factor 1 (IGF-1), etc.\n* Thyroid hormone replacement therapy (if applicable) received prior to randomization should be maintained on a stable regimen for at least 4 weeks.\n* The legal guardian understands and signs the informed consent form; participants aged ≥ 8 years shall also sign the informed consent form. For participants aged under 8 years who are capable of expressing assent, their assent shall be clearly documented.\n\nExclusion Criteria:\n\n* Subjects with closed epiphyses.\n* Patients with Turner syndrome carrying Y chromosome or Y-chromosome-derived fragments and without gonadectomy.\n* Other types of growth and development abnormalities, including but not limited to growth hormone deficiency (GHD), Noonan syndrome, Prader-Willi syndrome, and growth retardation caused by malnutrition.\n* Participation in any other clinical trial within 3 months prior to screening with pharmacological or non-pharmacological intervention received.\n* Inhaled glucocorticoids used continuously for more than 2 weeks, or oral\u002Fintravenous glucocorticoids used continuously for more than 1 week within 3 months prior to screening.\n* Receiving other treatments that may affect growth, including but not limited to methylphenidate, sex hormones, gonadotropin-releasing hormone analogs, aromatase inhibitors, anabolic agents, etc.\n* Abnormal liver and renal function at screening (ALT \\> 2 times the upper limit of normal; Cr \\> upper limit of normal).\n* Subjects with abnormal glucose metabolism, including: a. Diagnosed diabetes mellitus; b. Fasting blood glucose ≥ 6.1 mmol\u002FL on two consecutive measurements; c. Glycated hemoglobin (HbA1c) ≥ 6.5%; d. Impaired glucose tolerance judged by the investigator as unsuitable for participation in this study.\n* Presence of chronic infectious diseases judged by the investigator to interfere with study participation, such as chronic hepatitis B.\n* Subjects with systemic chronic diseases, such as chronic kidney disease, severe cardiovascular diseases (e.g., aortic dissection, uncontrolled hypertension), psychiatric and psychological disorders.\n* Subjects with severe congenital skeletal dysplasia; or those with scoliosis \\> 20°, significant kyphosis, claudication, or a prior diagnosis of slipped capital femoral epiphysis.\n* Subjects with a prior history of intracranial hypertension.\n* Subjects with a history of malignant tumor or current active malignant tumor, including intracranial tumors.\n* Known hypersensitivity to growth hormone or its excipients.\n* Subjects with celiac disease who have not maintained a gluten-free diet within 12 months prior to screening.\n* Any other conditions deemed inappropriate for enrollment in this clinical trial by the investigator.","FEMALE",{"count":135,"type":20},84,[59],"This is a multicenter, randomized, open-label, positive-controlled phase III confirmatory clinical study. A total of 84 children with short stature due to Turner Syndrome (TS) are planned to be enrolled. Stratified by age and karyotype, subjects will be randomized at a 1:1 ratio to either the test group or the positive control group with continuous treatment for 52 weeks. The study aims to compare the efficacy and safety of Inpegsomatropin-Injection versus Givopegsomatropin Solution Injection in children with TS-related short stature, so as to provide evidence for the new indication application of the investigational drug.",[24],[140,141],"Inpegsomatropin Injection","Givopegsomatropin Solution Injection","NOT_YET_RECRUITING","2026-05-28",{"date":145,"type":38},"2026-06-02",{"date":147,"type":20},"2026-06-15",{"date":149,"type":20},"2030-02-28",{"name":151,"class":93},"Xiamen Amoytop Biotech Co., Ltd.",51,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":133,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":57,"phases":164,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":46},"100596158","phase-2-a-study-comparing-different-treatment-approaches-for-the-initiation-of-puberty-in-girls-with-turner-syndrome-using-a-trifecta-dared-approach-for-rare-diseases-100596158","NCT07041814","A Study Comparing Different Treatment Approaches for the Initiation of Puberty in Girls With Turner Syndrome Using a TRIFECTA-DARED Approach for Rare Diseases","Bayesian Pragmatic Trial for Pubertal Induction in Turner Syndrome: TRansformation Initiative For Efficient Clinical TriAl Design Advancement in RarE Diseases (TRIFECTA-DARED Framework)","TRIFECTA-DARED","Inclusion Criteria:\n\n1. Females aged 11-30 years old with karyotype-verified (45, X or other similar karyotypes) and clinically confirmed Turner's syndrome prior at the time of pubertal induction\n2. Confirmed estrogen deficiency with primary ovarian failure (high level of follicular stimulating hormone (FSH \\> 25 IU\u002FL))\n3. Patients who have not undergone pubertal development ( no breast development and underdeveloped uterus size).\n4. Hormone Replacement Therapy (HRT)-naive TS patients\n5. Breast Tanner Stage of 2 or less.\n6. Patients on Growth Hormone (GH) will be allowed entry into the study.\n7. Consented to trial participation (from individual TS patients (if aged 18 and above) or the parents or guardians (for under-18 TS patients) with individual's assent\n\nExclusion Criteria:\n\n1. Patients with signs of spontaneous puberty\n2. Contraindications to trial products (e.g hypersensitivity to any components of the HRT) based on the most recent version of the British National Formulary (BNF 85)\n3. Previous history of exposure to estrogen treatment.\n4. Concomitant use of other drugs that affect the bone mineral density (BMD) of the participants (e.g. Bisphosphonates or prolonged use of systemic corticosteroids). Vitamin D supplementation and short corticosteroid usage are allowed.\n5. Acute or chronic hepatic disease\n6. Patients with untreated hypothyroidism\n7. Inflammatory bowel disease (Ulcerative Colitis, Crohn's disease) and coeliac disease\n8. Cigarette-smoking patients\n9. Severely obese patients based on the following criteria:\n\n   1. For TS patients aged 11-17 years old: Based on the WHO chart with BMI \\> 95th percentile\n   2. For TS patients aged 18 years until 30 years: BMI of 37.5 or above based on the Malaysian Clinical Practice Guideline for the Management of Obesity\n10. Unknown abnormal genital bleeding\n11. Porphyria\n12. Recent involvement with clinical research studies (previous 6 months) investigating new HRT formulations","11 Years","30 Years",{"count":5,"type":20},[165],"PHASE2","Turner syndrome is a condition in which a girl's body does not make enough estrogen on its own, so doctors give estrogen to help start breast and uterine (womb) development. Hence, the goal of this clinical trial is to learn whether two different ways of giving estrogen help girls and young women with Turner syndrome go through puberty normally, and to compare how well each method works and how safe they are.\n\nThe main questions the trial aims to answer are:\n\n1. Does taking an oral estrogen tablet (Progynova) or applying an estrogen gel (Oestrogel) lead to better breast development?\n2. Does one method lead to a larger uterine size as seen on ultrasound?\n3. Do participants start menstrual-like (withdrawal) bleeding, and does one method cause it sooner?\n4. What side effects (for example, headaches, nausea, changes in blood tests) happen with each method?\n\nWho can take part?\n\n* Girls and young women aged 11-30 years with a confirmed diagnosis of Turner syndrome and no previous estrogen treatment.\n* They have not yet begun puberty (no breast growth, and a small uterus on ultrasound).\n* They agree to adhere to the study schedule and keep a diary of any bleeding or side effects\n\nWhat will happen to the participants during the clinical trial?\n\n* Get assigned at random to one of two groups (1:1 ratio):\n\n  1. Gel group: Apply Oestrogel (17β-estradiol) to the skin, starting twice a week, then daily with increasing doses over 19 months.\n  2. Tablet group: Swallow Progynova (estradiol valerate) tablets, starting twice a week, then daily with increasing doses over 19 months.\n* Visit the clinic at the start of study (baseline), month 1, 7, 13, and 19 for:\n\n  1. A physical exam (including breast staging).\n  2. An ultrasound to measure uterine length and thickness.\n  3. A blood test for safety checks (triglycerides and other markers).\n  4. Keep a diary noting any spotting or bleeding (called withdrawal bleeding) and any side effects.\n\nWhy does this matter?\n\nGirls and young women with Turner syndrome often need estrogen to begin puberty safely. This trial will show which method-gel or tablets-best mimics natural puberty (breast and uterine growth), how quickly menstrual-like bleeding begins, and which has fewer unwanted effects. The findings will help doctors choose the most effective and safe treatment for people with Turner syndrome.",[24],[24,169,170,171,172,173,174],"Hormone Replacement Therapy","Progynova","Oestrogel","Transdermal 17β Estradiol","Estradiol Valerate","Pubertal Induction","2026-01-28",{"date":177,"type":38},"2026-02-02",{"date":179,"type":20},"2026-02-15",{"date":181,"type":20},"2029-10-31",{"name":183,"class":184},"Universiti Kebangsaan Malaysia Medical Centre","OTHER",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":192,"sex":133,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":46},"100555047","genetic-and-epigenetic-background-of-inner-ear-dysfunction-in-turner-syndrome-100555047","NCT06507007","Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner Syndrome","EPIHEAR","Inclusion Criteria:\n\n* age between 18 and 60 years old\n\nExclusion Criteria:\n\n* Contraindications for the MRI or CBCT\n* Serious medical disorders\n* Neurological or psychiatric disorders of any kind\n* Use of medication that is known to influence inner ear function\n* Medical history with dizziness or hearing problems (controls only)",true,"18 Years","60 Years",{"count":196,"type":20},150,"The goal of this case-control study is to pave the way for new revolutionary treatment measures within hearing loss that could either replace or delay the need for hearing aids. The study focuses on people with Turner syndrome (TS).\n\nThe aim is to find out if there are specific DNA methylation patterns and\u002For RNA expression profiles linked to sensorineural hearing loss (SNHL) in people with TS. Additionally, the structure and function of the inner ear in these individuals will be examined to see if there is a connection to their epigenetic profile.\n\nThe main question it aims to answer is: Does epigenetics constitute a common denominator for some of the unexplained SNHL cases?\n\nTurner Syndrome (TS) represents an ideal model for studying epigenetics related to sensorineural hearing loss (SNHL).\n\nParticipants will undergo the following tests:\n\n* Ear examinations\n* Hearing tests\n* Balance tests\n* Blood tests\n* MRI scans\n* CBCT (cone-beam computed tomography) scans",[199,24,200],"Sensorineural Hearing Loss","Inner Ear Disease",[202,203,24,204],"Epigenetics","Sensorineural hearing loss","Inner Ear Dysfunction","2026-01-24",{"date":207,"type":38},"2026-01-27",{"date":209,"type":38},"2025-02-01",{"date":211,"type":20},"2027-07-30",{"name":213,"class":184},"Gødstrup Hospital",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":133,"minAge":193,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":46},"100619391","parental-project-amongst-93-patients-with-turner-syndrome-100619391","NCT07344012","Parental Project Amongst 93 Patients With Turner Syndrome","TURNER","Inclusion Criteria:\n\n* Adult women (≥18 years old)\n* Treated at Strasbourg University Hospitals for a parental project during the period from January 1, 2009, to December 31, 2019\n* Having presented with Turner syndrome confirmed by karyotyping\n* Having expressed a desire to become a parent during consultation\n\nExclusion Criteria:\n\n* No desire to become a parent or missing data\n* Missing data","40 Years",{"count":223,"type":20},93,"The aim is to describe the parental project, spontaneous pregnancies and pregnancies resulting from egg donation or adoption in women diagnosed with Turner syndrome treated at Strasbourg University Hospitals.",[24],[24],"2026-01-07",{"date":229,"type":38},"2026-01-15",{"date":231,"type":38},"2025-11-18",{"date":233,"type":20},"2027-11-18",{"name":235,"class":184},"University Hospital, Strasbourg, France",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":133,"minAge":101,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":57,"phases":247,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":46},"100580230","phase-4-bleeding-patterns-in-sequential-and-continuous-progesterone-supplementation-in-adolescents-with-turner-syndrome-100580230","NCT06834594","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome","Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome: A Non-randomized Prospective Trial (The BOOST Study)","BOOST","Inclusion Criteria:\n\n* Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.\n* Prescribed adult dosing\\* of transdermal or oral estradiol for estrogen replacement therapy.\n\n  \\*Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200μg\u002Fday of transdermal estradiol, or (i.e. 50-200μg\u002Fday of transdermal estradiol or 2-4mg\u002Fday oral estradiol).\n* Have achieved menarche.\n\nExclusion Criteria:\n\n* Disclosure of sexual activity and desire for contraception.\n* Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.\n* Having received depot medroxyprogesterone within one year prior to study recruitment.\n* Non-English or non-Spanish speaking.","20 Years",{"count":246,"type":20},40,[248],"PHASE4","This is a single-site open label non-randomized study comparing effects of sequential versus continuous use of progesterone supplementation amongst Turner Syndrome (TS) patients with primary ovarian insufficiency (POI) prescribed hormone replacement therapy (HRT).",[24,251],"Primary Ovarian Insufficiency (Poi)",[253,254,255],"Turner syndrome","Primary ovarian insufficiency","Hormone replacement therapy","2025-08-27",{"date":258,"type":38},"2025-09-04",{"date":260,"type":38},"2025-07-31",{"date":262,"type":20},"2026-07-31",{"name":264,"class":184},"Children's Mercy Hospital Kansas City",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":133,"minAge":193,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":46},"100529831","role-of-cardiac-angiomr-in-diagnosis-of-cardiac-and-vascular-anomalies-in-adult-patients-with-turner-syndrome-100529831","NCT06178887","Role of Cardiac AngioMR in Diagnosis of Cardiac and Vascular Anomalies in Adult Patients with Turner Syndrome","Role of Cardiac Magnetic Resonance Angiography (1.5-T) in the Diagnosis of Cardiac and Thoraco-abdominal Vascular Tree Anomalies in Adult Patients with Turner Syndrome","Inclusion Criteria:\n\n* confirmed diagnosis of Turner Syndrome\n* patients underwent angioMR 1.5 T\n* age \\> 18 years",{"count":273,"type":20},33,"Considering the high prevalence of cardiovascular disease in Turner syndrome patients, noninvasive cardiac imaging is crucial for diagnosis and follow-up. From the review of the literature, it was evident that the imaging techniques used involved the evaluation of only the thoracic findings, in particular the heart and the thoracic aorta, while no data are currently available on the distal abdominal aorta or iliac arteries, since ultrasound and MRI are interrupted at the diaphragmatic level.",[276,24],"Anomaly Heart","2025-03-12",{"date":279,"type":38},"2025-03-14",{"date":281,"type":38},"2019-01-08",{"date":283,"type":20},"2025-12-31",{"name":285,"class":184},"Azienda Ospedaliero-Universitaria di Modena",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":133,"minAge":193,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":46},"100577122","characterization-of-hepatopathy-in-turner-syndrome-analysis-of-determinants-100577122","NCT06794190","Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants","Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants in an Observational Study","Inclusion Criteria:\n\n* Diagnosis of Turner syndrome made by karyotype analysis on peripheral blood.\n* Age 18 years or older\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* TS patients on therapy with drugs responsible for significant liver enzyme alterations (liver function alteration, LFA).",{"count":294,"type":20},120,"The present study is therefore aimed at investigating the prevalence of hepatic alterations (laboratory and imaging) in adult patients with TS and generating hypothesissto the possible etiopathogenetic factors most involved, as well as evaluating the correlation between biochemical and structural abnormalities.\n\nThus, the study could provide relevant etiopathogenetic and prognostic results on the development of hepatopathy in TS patients.",[24],"2025-01-24",{"date":299,"type":38},"2025-01-27",{"date":301,"type":38},"2025-01-07",{"date":227,"type":20},{"name":304,"class":184},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":133,"minAge":311,"maxAge":193,"enrollmentInfo":312,"targetDuration":4,"studyType":57,"phases":314,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":46},"100576071","cardiopulmonary-exercise-testing-in-girls-8-18y-with-turner-sydrome-100576071","NCT06780514","Cardiopulmonary Exercise Testing in Girls (8-18y) with Turner Sydrome.","Inclusion Criteria:\n\n* Turner syndrome girls aged 8-18 years old\n\nExclusion Criteria:\n\n* Severe mental impairement making it impossible to perform an exercise test","8 Years",{"count":313,"type":20},20,[315],"NA","The goal of this clinical trial is to have a beter insight in the exercise tolerance in girls with Turner Syndrome aged 8-18 years . The main question it aims to answer is:\n\nIs there a difference in VO2 max comparing Turner syndrome girls with standard values? How do cardiovascular parameters change during exercise (heart rate, bloodpressure, ...)\n\nParticipants will perform a cyclo-ergometry in a standardised way.",[24],[319],"Cardiopulmonary exercise test","2025-01-13",{"date":322,"type":38},"2025-01-17",{"date":324,"type":38},"2024-01-31",{"date":326,"type":20},"2026-07-30",{"name":328,"class":184},"University Hospital, Ghent",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":133,"minAge":336,"maxAge":337,"enrollmentInfo":338,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":340,"conditions":341,"keywords":346,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":357},"100348141","neuropsychological-assessment-of-children-and-adolescents-with-turner-syndrome-100348141","NCT03812913","Neuropsychological Assessment of Children and Adolescents With Turner Syndrome","ENEAST","INCLUSION CRITERIA\n\nTurner syndrome group :\n\n* girls with diagnosed Turner syndrome.\n\nIsolated GHD group :\n\n* girls with diagnosed isolated growth hormone deficiency\n\nAll participants :\n\n* age between 7 years to 16 years and 11 months.\n* informed consent signed by the participant and her parents (or her legal representatives)\n* being registered in the national social security system\n\nEXCLUSION CRITERIA :\n\nTurner syndrome group :\n\n* patients with chronic pathology other than Turner syndrome.\n* karyotype : part of a Y chromosome and r(X) cases.\n* medical treatment other than those usually prescribed in patients with Turner syndrome.\n\nIsolated GHD group :\n\n* patients with chronic pathology other than isolated growth hormone deficiency.\n* medical treatment other than those usually prescribed in patients with isolated growth hormone deficiency.\n\nAll participants :\n\n* diagnosed intellectual disability (IQ\\\u003C70) or intellectual giftedness\n* history of acquired brain injury\n* sensory disturbances (auditory or visual) incompatible with the achievement of neuropsychological tasks.\n* insufficient French language proficiency","7 Years","16 Years",{"count":339,"type":20},70,"Turner syndrome (TS) is a rare chromosomal disorder characterized by partial or complete loss of one of the X chromosomes that affects about one in every 2000 female babies born. These young patients described difficulties making friends, understanding others' emotions and intentions, and controlling their own emotions. Difficulties in these domains could led to social withdrawal, to reduced social skills and could have a significant impact on self esteem and mental health as well as on long-term academic and social functioning in affected individuals. The purpose of this project is to identify functional and dysfunctional cognitive and socio-cognitive abilities in these young patients which could account social difficulties described by some of them and their family. To this end, 35 girls with TS and 35 girls with isolated growth hormone deficiency and normal cerebral MRI will be recruited. Subjects will be 7 to 16 years and 11 months of age. Socio-cognitive and cognitive functions will be assessed with neuropsychological and experimental tasks. Questionnaires completed by patient, parents or teacher, will evaluate social and behavioral functioning.",[24,342,343,344,345],"Isolated Growth Hormone Deficiency","Cognitive Functions","Social Cognition","Pediatrics",[253,343,344,345],"2024-12-26",{"date":349,"type":38},"2024-12-30",{"date":351,"type":38},"2019-09-05",{"date":353,"type":20},"2025-12-05",{"name":355,"class":356},"University Hospital, Angers","OTHER_GOV",3,{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":133,"minAge":4,"maxAge":4,"enrollmentInfo":366,"targetDuration":244,"studyType":21,"phases":4,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":379},"100443300","inspiring-new-science-in-guiding-healthcare-in-turner-syndrome-registry-100443300","NCT05052606","Inspiring New Science In Guiding Healthcare in Turner Syndrome Registry","INSIGHTS Registry - Inspiring New Science In Guiding Healthcare in Turner Syndrome","INSIGHTS","Inclusion Criteria:\n\n1. Individuals with TS and TS variants as defined by the TS Clinical Practice Guideline definition (karyotype consistent with TS, phenotypic female, clinical feature(s) of TS)\n2. Informed consent\u002Fassent as appropriate\n\nExclusion Criteria:\n\na. Lack of a TS diagnosis on file",{"count":367,"type":20},5000,"INSIGHTS is a registry research study that collects key information on medical history for girls and women with Turner syndrome and the clinical care they receive. This includes genetic tests, imaging, medications, and more for hundreds of patients seen at a number of clinics across the US. In addition to learning a lot about the current state of health for individuals with TS, INSIGHTS serves as an infrastructure to conduct future studies are meaningful to patients and their families.",[24],"2024-09-27",{"date":372,"type":38},"2024-10-01",{"date":374,"type":38},"2020-05-20",{"date":376,"type":20},"2025-10",{"name":378,"class":184},"University of Colorado, Denver",10,{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":133,"minAge":193,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":57,"phases":390,"briefSummary":391,"conditions":392,"keywords":396,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":46},"100557927","phase-4-determining-dose-equivalence-between-oral-and-transdermal-estrogen-treatment-in-women-with-turner-syndrome-100557927","NCT06544473","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome","Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome - A Randomized Study","Inclusion Criteria:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nExclusion Criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy","50 Years",{"count":389,"type":20},50,[248],"This 5-week, phase IV randomized crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The objective is to establish the equipotency between the two estradiol regimens by evaluating various estradiol-dependent surrogate markers. The study involves 50 women with TS, aged 18-50 years, who are randomized to receive either oral or transdermal ERT for 14 days, followed by a crossover to the alternate treatment for another 14 days, with a one-week washout period in between. Blood tests are conducted at baseline, after the first 14 days of treatment, after the washout period, and after the final 14 days of treatment. The investigators anticipate that this study will provide clinicians with a better understanding of ERT in treating women with TS.",[24,393,169,394,395],"Hypogonadism; Ovarian","Estrogen Replacement Therapy","Estrogen Deficiency",[253,169,394,397,398],"Estrogen treatment","Dose equipotency","2024-08-22",{"date":401,"type":38},"2024-08-23",{"date":403,"type":38},"2021-11-29",{"date":405,"type":20},"2026-12-31",{"name":407,"class":184},"Aarhus University Hospital",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":192,"sex":133,"minAge":193,"maxAge":387,"enrollmentInfo":415,"targetDuration":4,"studyType":57,"phases":416,"briefSummary":417,"conditions":418,"keywords":419,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":426,"locationsCount":46},"100559924","phase-4-long-term-effects-of-oral-versus-transdermal-estrogen-replacement-therapy-in-turner-syndrome-100559924","NCT06570460","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome","Long Term Effects of Oral Versus Transdermal Estrogen Replacement Therapy in Turner Syndrome - A Randomized Trial","Inclusion criteria:\n\nFor participants with TS:\n\n* Diagnosis of TS regardless of karyotype\n* Age 18-50 years\n* Already receiving estrogen treatment\n\nFor healthy controls:\n\n* Female\n* Age 18-50 years\n* Previously healthy\n* Not receiving any medication\n* Not using any form of contraceptive pills\n* No mental or psychiatric disorders\n\nExclusion criteria:\n\n* Active systemic chronic diseases\n* Known or suspected breast cancer\n* Known or suspected estradiol-dependent tumors (endometrial cancer or similar)\n* Untreated endometrial hyperplasia\n* Current or previous venous thromboembolism\n* Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more\n* Known hypersensitivity to the medications used\n* Pregnancy\n* Menopause (for the control group only)",{"count":389,"type":20},[248],"This 14-month, phase IV, randomized controlled crossover trial aims to compare the effects of oral versus transdermal estrogen replacement therapy (ERT) in women with Turner syndrome (TS). The study's objectives are to clarify endocrine, metabolic, cardiovascular, and thromboembolic risk factors in TS after a wash-out period without estrogen (E2) treatment; compare the effects of oral versus transdermal (TD) ERT regimens; and examine the long-term effects of E2 administration via these two routes. The study involves 50 TS women aged 18-50 years and 50 control participants. TS participants are randomized to receive either oral or TD ERT for six months, followed by crossover to the alternate treatment for another six months. Prior to randomization, any existing ERT will be discontinued for a 1-month washout period. A second 1-month washout period will occur between the two 6-month treatment phases. Laboratory analyses and clinical investigations are performed after the first wash-out period, after the first six months of treatment, and after the last six months of treatment. We anticipate that this study may provide a basis for new and improved recommendations for sex hormone replacement therapy in TS.",[24,393,169,394,395],[253,255,420,397,421],"Estrogen replacement therapy","Long term side effects",{"date":423,"type":38},"2024-08-26",{"date":403,"type":38},{"date":405,"type":20},{"name":407,"class":184},{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":133,"minAge":434,"maxAge":161,"enrollmentInfo":435,"targetDuration":4,"studyType":57,"phases":436,"briefSummary":437,"conditions":438,"keywords":439,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":46},"100504519","phase-2-vosoritide-for-short-stature-in-turner-syndrome-100504519","NCT05849389","Vosoritide for Short Stature in Turner Syndrome","Vosoritide for Treatment of Short Stature in Girls With Turner Syndrome","Inclusion Criteria:\n\n1. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, subjects under the age of 18 are willing and able to provide assent (if required) after the nature of the study has been explained and prior to performance of any research-related procedure.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Age \\>3 years 0 days AND \\\u003C10 years 364 days\n4. Pre-pubertal defined as Tanner Stage 1 breasts in females.\n5. Patient height \\\u003C-2 SDS. All height SDS values are calculated using the CDC growth charts\u002Fdata tables.\n6. Patients must have a confirmed diagnosis of Turner Syndrome based on a karyotype with a minimum of 30 cells or on a chromosomal microarray. Subjects with Turner Syndrome mosaicism (such as a 46,XX\u002F45,X karyotype) must have a minimum of 10% mosaicism of 45,X cell line in order to participate in the study.\n7. Subjects must either be naïve to growth hormone or have a poor response to growth hormone therapy defined as either:\n\n   1. Subjects completed at least one year of treatment with GH and first year height velocity (HV) below -1 SD according to the National Cooperative Growth Study TS 1st year response to growth hormone height velocity curve.\n   2. Subjects receiving GH for more than a year with AGV in the last 6 months \\\u003C 50%ile for US girls for age\u002Fsex). Subjects meeting this criterion are no longer showing catch up growth and may benefit from an alternative form of therapy.\n\nExclusion Criteria:\n\n1. Growth plate fusion - Defined as a bone age via the Greulich and Pyle method of 13 years. These patients have limited remaining growth potential.\n2. Concomitant treatment with growth hormone or recombinant insulin-like growth factor-1 (IGF-1). Patients may have been previously treated with growth hormone or IGF-1 therapy. If the patient is currently on one of these therapies, they will be required to discontinue at least 1 week prior to the screening visit. That decision will be deferred to their treating clinical endocrinologists in conjunction with the patient's guardians. We anticipate that only patients who are having a poor response to their therapy will be interested in enrolling in the current study as there is no rationale for a patient who is receiving growth hormone therapy and having a positive response to enroll in the current study.\n3. Prior or concomitant treatment with any form of estrogen, gonadotropin-releasing hormone (GnRH) analog, aromatase inhibitor or oxandrolone\n4. History of any type of malignancy\n5. Subjects known to have Y-chromosome material unless they have undergone gonadectomy and have fully external female genitalia\n6. Chronic medical condition known to affect growth including but not limited to:\n\n   A. Cystic fibrosis B. Diabetes C. Inflammatory Bowel Disease D. Untreated Celiac Disease - If a subject has been diagnosed with celiac disease and has been on a gluten free diet for \\>12 months and has a tissue transglutaminase antibody within the normal range at screening, then they are eligible for the trial.\n\n   E. Asthma requiring a daily inhaled steroid dose \\> 400 micrograms of inhaled budesonide per day or equivalent F. Taking daily oral glucocorticoids for any reason G. Note - Attention Deficit hyperactivity Disorder (ADHD) treated with a stimulant and treated hypothyroidism with a normal thyroid stimulating hormone (TSH) will NOT exclude the subject from participating in the trial. Subjects on either stimulant medication or thyroid hormone replacement must be on a stable dose for 3 months prior to the screening visit.\n\n   H. Congenital heart disease which places the subject at increased risk of an adverse cardiac outcome in the setting of hypotension including but not limited to: hypertrophic cardiomyopathy, aortic stenosis with peak gradient \\>50mmHg, severe aortic regurgitation (defined as pressure half time \\>500ms by echocardiogram), coronary insufficiency, or any anatomy with a need for an afterload reducing agent. Any patient with baseline abnormalities on echocardiogram will be reviewed with a pediatric cardiologist for appropriateness for inclusion in the study.\n7. Malnutrition - Defined as a BMI \\\u003C5th percentile (CDC growth charts)\n8. Any clinically significant abnormality on screening tests as determined by the principal investigator. Abnormal screening labs may be repeated up to 3 months after the screening visit. If those labs are normal on repeat, the subject may proceed into the trial.\n9. Known or suspected allergy to trial medication, excipients, or related products\n10. The receipt of any investigational drug within 90 days prior to this trial","3 Years",{"count":313,"type":20},[165],"Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the short-stature homeobox-containing (SHOX) gene. Growth hormone (GH) is an approved therapy for this condition, although not associated with GH deficiency, and benefits are modest. Vosoritide, a C-type natriuretic peptide (CNP) analog, targets chondrocytes within the growth plate leading to increased cell proliferation and hypertrophy. We hypothesize that patients with TS and short stature will respond to vosoritide treatment leading to increased growth velocity. This study will enroll pre-pubertal girls with TS who are either naïve to GH or have had a poor response to GH therapy. All subjects will be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes. Annualized growth velocity (AGV) on vosoritide will be compared to AGV in the 6-18 months prior to initiation of vosoritide based on historical data available in the medical record. Subjects with a positive response to therapy will be given the option to continue in the extension phase of the study during which they will continue to receive vosoritide until growth cessation.",[24,68],[253,68,440],"Vosoritide","2024-06-20",{"date":443,"type":38},"2024-06-24",{"date":445,"type":38},"2024-04-12",{"date":447,"type":20},"2026-09",{"name":449,"class":184},"Roopa Kanakatti Shankar, MBBS, MS",{"id":451,"slug":452,"hasResults":11,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":192,"sex":133,"minAge":16,"maxAge":54,"enrollmentInfo":457,"targetDuration":4,"studyType":57,"phases":459,"briefSummary":460,"conditions":461,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":46},"100496157","the-danish-turner-cryopreservation-study-100496157","NCT05740579","The Danish TURNER Cryopreservation Study","DANTE","Inclusion Criteria:\n\n* 45,X karyotype or other Turner variant karyotypes (45,X\u002F46,XX mosaicism, ring X mosaicism, isochromosome X)\n* Age 2-17 years old\n* Ability to participate in a physical examination including a cardiac examination.\n* Signed consent from both parents.\n\nExclusion Criteria:\n\n* Severe cardiac disease which inhibits safe surgery and pregnancy.\n* Karyotype with Y chromosome material\n* Mental retardation",{"count":458,"type":20},100,[315],"The goal of this clinical trial is to investigate if cryopreservation of ovarian tissue in girls with Turner syndrome can improve their fertility and lead to increased number of liveborn babies of Turner syndrome mothers. Women with Turner syndrome suffer from premature ovarian insufficiency which leads to infertility and lack of estrogen.\n\nThe main questions it aims to answer are:\n\n* Does the number of pregnancies and liveborn children increase after cryopreservation of ovarian tissue in turner syndrome?\n* Is the possible to predict when a girl with Turner syndrome reach menopause using monitoring of sex hormones?\n* Is it possible to identify any genes causing ovarian failure in Turner syndrome females?\n\nParticipants between 2-18 years old will be asked to participate in a laparoscopic surgery and removal of one ovary in order to cryopreserve the tissue until adulthood. The the cortical tissue will be autotransplanted in order to preserve fertility. The participant will during the study period be monitored using sex hormones.\n\nFurthermore, the investigators wish to investigate the ovarian tissue using RNA sequencing and DNA methylation analysis.\n\nNo comparison group is present.",[462,24,463],"Fertility Disorders","Premature Ovarian Failure","2024-05-23",{"date":466,"type":38},"2024-05-24",{"date":468,"type":38},"2023-01-01",{"date":470,"type":20},"2051-01-01",{"name":472,"class":184},"University of Aarhus",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":478,"eligibilityCriteria":479,"healthyVolunteers":192,"sex":133,"minAge":193,"maxAge":102,"enrollmentInfo":480,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":46},"100541112","lymphedema-low-grade-inflammation-and-the-vasculature-in-turner-syndrome-100541112","NCT06325618","Lymphedema, Low-grade Inflammation and the Vasculature in Turner Syndrome","TSCOR_V","Inclusion Criteria:\n\n* Turner Syndrome\n\nExclusion Criteria:\n\n* pregnancy\n* contraindications for MRI",{"count":196,"type":20},"100 women with karyotype verified TS, previously examined at 4 study visits during a 19-year period will be asked to participate in a 5th study visit. Healthy age-matched females will be included as controls in a ratio 2:1.\n\nThe aim is to examine and quantify the cardiovascular and lymphatic system in women with TS. The investigators will study a possible causal mechanism between the known pathologic phenotype and alterations in these systems to understand, prevent or treat the life-threatening complications in TS.",[24,483,484,485],"Cardiovascular Diseases","Lymphedema","Inflammation","2024-03-15",{"date":488,"type":38},"2024-03-22",{"date":490,"type":38},"2024-01-08",{"date":492,"type":20},"2027-08",{"name":472,"class":184},{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":11,"sex":133,"minAge":16,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":57,"phases":503,"briefSummary":504,"conditions":505,"keywords":506,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":508,"lastUpdatePostDateStruct":509,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":516},"100531672","identification-of-y-chromosome-from-free-circulating-dna-in-patients-with-turner-syndrome-100531672","NCT06202846","Identification of Y Chromosome From Free Circulating DNA in Patients With Turner Syndrome","Turner-Ylc","Inclusion Criteria:\n\n* patient aged 2 to 74 years\n* with a diagnosis of Turner syndrome confirmed by karyotype\n* who have given their consent or whose legal representative(s) have given their consent(s) consent(s) to participate in the study\n* affiliated to the French Social Security system or benefiting from such a system\n\nExclusion Criteria:\n\n* male phenotype\n* patient or legal representative(s) with comprehension difficulties (linguistic, etc.)\n* patients covered by articles L.1121-5 to L.1121-8 of the CSP (French Public Health Code)","74 Years",{"count":389,"type":20},[315],"Turner syndrome affects 1\u002F2500 female newborns. It is characterized by a short stature, gonadal dysgenesis and bone anomalies. It is secondary to X chromosome abnormality. The clinical course can be marked by various complications, including degeneration of gonadal streaks into cancer (gonadoblastoma). The risk of gonadoblastoma is increased by the presence of Y chromosome, with a risk of 19 to 43%. However, Y chromosome material may be difficult to identify due to its mosaic state, at varying rates depending on the tissue. Free circulating DNA (cfDNA) corresponds to fragments of extracellular DNA present in the plasma, released into the circulation during cell death processes by the various tissues of the body. Due to its multiple tissue origins and easy collection, cfDNA appears to be a suitable matrix for searching for low mosaic Y chromosome sequences in patients with Turner syndrome.\n\nThe main objective of the study is to develop a cfDNA-based test to look for Y chromosome sequences in 50 patients with Turner syndrome. The secondary objectives are to determine the mosaic detection threshold of this test and to compare the performance of this test with the fluorescence in situ hybridization (FISH) technique used in routine diagnosis.\n\nThis study will assess the detection sensitivity of this test and its relevance in a clinical context.",[24],[253,507],"Y chromosome","2024-03-05",{"date":510,"type":38},"2024-03-06",{"date":512,"type":38},"2024-02-28",{"date":514,"type":20},"2028-10",{"name":235,"class":184},2,{"id":518,"slug":519,"hasResults":11,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":133,"minAge":4,"maxAge":4,"enrollmentInfo":523,"targetDuration":524,"studyType":21,"phases":4,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":527,"lastUpdatePostDateStruct":528,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":46},"100300026","uthealth-turner-syndrome-research-registry-100300026","NCT03185702","UTHealth Turner Syndrome Research Registry","Inclusion Criteria:\n\n* Diagnosis of Turner Syndrome\n\nExclusion Criteria:\n\n* Diagnosis excluding Turner Syndrome",{"count":19,"type":20},"10 Years","The investigators will conduct genetic comparisons between Turner Syndrome (TS) patients with and without Bicuspid Aortic Valve (BAV) to identify causative agents of BAV in people with TS.\n\nThe investigators will correlate the patterns and prevalence of structural heart defects in TS women with emerging molecular data to identify patients who are at high risk for cardiovascular complications",[24],"2023-11-27",{"date":529,"type":38},"2023-11-28",{"date":531,"type":38},"2015-08-28",{"date":533,"type":20},"2035-01-01",{"name":535,"class":184},"The University of Texas Health Science Center, Houston",{"id":537,"slug":538,"hasResults":11,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":542,"eligibilityCriteria":543,"healthyVolunteers":192,"sex":15,"minAge":544,"maxAge":244,"enrollmentInfo":545,"targetDuration":4,"studyType":57,"phases":547,"briefSummary":548,"conditions":549,"keywords":558,"overallStatus":142,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":571},"100381852","growing-up-with-the-young-endocrine-support-system-yess-100381852","NCT04252001","Growing up With the Young Endocrine Support System (YESS!)","Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care","YESS","Inclusion Criteria:\n\n* Aged 15 to 20 years old.\n* Diagnosed with congenital adrenal hyperplasia, hypogonadotropic hypogonadism, Turner syndrome, Klinefelter syndrome, growth hormone deficiency, combined pituitary hormone deficiency, Androgen insensitivity syndrome, thyroid dysgenesis or Addison's disease\n\nExclusion Criteria:\n\n* Lack of a mobile phone or tablet.\n* Intellectual disability or language barrier leading to inability to use the YESS! game or the control game.","15 Years",{"count":546,"type":20},160,[315],"Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game.",[550,551,552,553,24,554,555,556,557],"Congenital Adrenal Hyperplasia","Hypogonadotropic Hypogonadism","Growth Hormone Deficiency","Combined Pituitary Hormone Deficiency","Klinefelter Syndrome","Addison's Disease","Androgen Insensitivity Syndrome","Thyroid Dysgenesis",[559,560,561],"Serious game","Endocrinology","Transition","2023-09-06",{"date":564,"type":38},"2023-09-07",{"date":566,"type":20},"2024-12-01",{"date":568,"type":20},"2026-12-01",{"name":570,"class":184},"dr. Laura C. G. de Graaff-Herder",7,{"id":573,"slug":574,"hasResults":11,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":15,"minAge":193,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":46},"100398068","growing-up-with-rare-genetic-syndromes-100398068","NCT04463316","GROWing Up With Rare GENEtic Syndromes","GROWing Up With Rare GENEtic Syndromes ….When Children With Complex Genetic Syndromes Reach Adult Age","GROW UR GENES","Inclusion Criteria:\n\n* Patients with rare syndromes or rare congenital diseases visiting the multidisciplinary outpatient clinic for patients with rare diseases at the department of endocrinology, internal medicine, Erasmus Medical Center.\n\nExclusion Criteria:\n\n* None",{"count":581,"type":20},600,"Introduction Rare complex syndromes Patients with complex genetic syndromes, by definition, have combined medical problems affecting multiple organ systems, and intellectual disability is often part of the syndrome. During childhood, patients with rare genetic syndromes receive multidisciplinary and specialized medical care; they usually receive medical care from 3-4 medical specialists.\n\nIncreased life expectancy Although many genetic syndromes used to cause premature death, improvement of medical care has improved life expectancy. More and more patients are now reaching adult age, and the complexity of the syndrome persists into adulthood. However, until recently, multidisciplinary care was not available for adults with rare genetic syndromes. Ideally, active and well-coordinated health management is provided to prevent, detect, and treat comorbidities that are part of the syndrome. However, after transition from pediatric to adult medical care, patients and their parents often report fragmented poor quality care instead of adequate and integrated health management. Therefore, pediatricians express the urgent need for adequate, multidisciplinary adult follow up of their pediatric patients with rare genetic syndromes.\n\nMedical guidelines for adults not exist and the literature on health problems in these adults is scarce. Although there is a clear explanation for the absence of adult guidelines (i.e. the fact that in the past patients with rare genetic syndromes often died before reaching adult age), there is an urgent need for an overview of medical issues at adult age, for 'best practice' and, if possible, for medical guidelines.\n\nThe aim of this study is to get an overview of medical needs of adults with rare genetic syndromes, including:\n\n1. comorbidities\n2. medical and their impact on quality of life\n3. medication use\n4. the need for adaption of medication dose according to each syndrome\n\nMethods and Results This is a retrospective file study. Analysis will be performed using SPSS version 23 and R version 3.6.0.",[584,585,586,587,588,550,589,590,591,592,24,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,66,613],"Prader-Willi Syndrome","PWS-like Syndrome","Silver Russel Syndrome","Congenital Hypopituitarism","Klinefelter (XXY-)Syndrome","XXXXY Syndrome","XXYY Syndrome","XXXX Syndrome (Tetra-X Syndrome)","Disorders of Sex Development","46, XY DSD","Tuberous Sclerosis","Neurofibromatosis","Albright Hereditaire Osteodystrofie","Cornelia de Lange Syndrome","Saethre-Chotzen Syndrome","17p- Deletiesyndrome","VCF Syndrome","POLR3A Mutatie","Ohdo Syndrome","Jacobsen Syndrome \u002F 11 q Syndrome","Myrhe Syndrome","CHARGE Syndrome","1q25-32 Deletie","Bardet Biedl Syndrome","Rett Syndrome","22q11 Deletion Syndrome","Allan-Herndon-Dudley Syndrome","Kallmann Syndrome","Rare Bone Disorders","Williams-Beuren Syndrome","2023-09-04",{"date":562,"type":38},{"date":617,"type":38},"2018-10-01",{"date":619,"type":20},"2030-01-01",{"name":570,"class":184},{"id":622,"slug":623,"hasResults":11,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":628,"targetDuration":524,"studyType":21,"phases":4,"briefSummary":630,"conditions":631,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":633,"lastUpdatePostDateStruct":634,"startDateStruct":636,"completionDateStruct":638,"leadSponsor":640,"locationsCount":46},"100423808","long-term-safety-and-effectiveness-of-growtropin-ii-treatment-in-children-with-short-stature-100423808","NCT04798690","Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Open, Multi-center, Non-interventional, Prospective\u002F Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature","Inclusion Criteria:\n\n* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)\n* Children who has official height record at least 6 months prior\n\nExclusion Criteria:\n\n* Children with Epiphyseal closure",{"count":629,"type":20},2500,"This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.",[552,63,24,632],"Small for Gestational Age","2023-04-11",{"date":635,"type":38},"2023-04-12",{"date":637,"type":38},"2021-02-08",{"date":639,"type":20},"2031-12",{"name":641,"class":93},"Dong-A ST Co., Ltd.",{"id":643,"slug":644,"hasResults":11,"nctId":645,"briefTitle":646,"officialTitle":647,"acronym":648,"eligibilityCriteria":649,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":652,"conditions":653,"keywords":655,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":46},"100178992","long-term-safety-and-effectiveness-of-growth-hormone-with-ghd-ts-crf-sga--iss-and-pws-in-children-100178992","NCT01604395","Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children","An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. \u002F Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children","LGS","Inclusion Criteria:\n\n* short stature children aged 2 years or more\n* children with GHD,TS, CRF, SGA or ISS\n* written informed consent from the person, person's parent or legal guardian",{"count":651,"type":20},6000,"The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj.\u002FEutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).",[552,24,654,632,63],"Chronic Renal Failure",[656,657,658,659,660,661],"GHD","TS","CRF","SGA","ISS","PWS","2021-02-17",{"date":664,"type":38},"2021-02-21",{"date":666,"type":4},"2012-01",{"date":668,"type":20},"2032-12-31",{"name":670,"class":93},"LG Chem"]